Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398988 | 0.95 | CYP2D6 (0.55) | CYP2D6MTNR1AKCNH2MTNR1BKDM4E | |
| SCHEMBL3397409 | 0.87 | MTNR1A (0.65) | MTNR1AMTNR1BKDM4EMAPK1 | |
| SCHEMBL5096244 | 0.84 | S1PR2 (0.62) | CYP2D6MTNR1AMTNR1BKDM4EMAPK1 | |
| SCHEMBL5105375 | 0.81 | BCHE (0.65) | CYP2D6 | |
| SCHEMBL5105479 | 0.81 | ALDH1A1 (0.63) | CYP2D6MTNR1AMTNR1BKDM4EMAPK1 | |
| SCHEMBL3400228 | 0.81 | MTNR1A (0.68) | CYP2D6MTNR1AMTNR1BKDM4E | |
| SCHEMBL14195626 | 0.80 | S1PR2 (0.74) | GGPS1 | |
| SCHEMBL3195449 | 0.79 | CYP2D6 (0.56) | CYP2D6KCNH2KDM4EMAPK1 | |
| Trifluoroacetic Acid SCHEMBL949073 | 0.79 | CYP2D6 (0.52) | CYP2D6KCNH2KDM4EMAPK1GGPS1 | |
| Trifluoroacetic Acid SCHEMBL947515 | 0.79 | CYP2D6 (0.52) | CYP2D6KCNH2KDM4EMAPK1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221932-A1 | Methods and Uses of Melatonin Ligands | DOMINGUEZ LOPEZ SERGIO (US) | 2016-08-04 | — | — | US | claimed |
| EP-1973868-B1 | Novel elatonin ligands having antidepressant activity as well as sleep inducing properties | UNIV MCGILL (CA) | 2015-09-09 | — | — | EP | claimed |
| WO-2015021535-A1 | METHODS AND USES OF MELATONIN LIGANDS | GOBBI GABRIELLA (CA) | 2015-02-19 | — | — | WO | claimed |
| US-20150045442-A1 | NOVEL MELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES | GOBBI GABRIELLA (CA) | 2015-02-12 | — | — | US | claimed |
| US-20100267836-A1 | NOVEL MELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES | UNIVERSITA DEGLI STUDI DI MILANO (IT) | 2010-10-21 | — | — | US | claimed |
| US-20160221932-A1 | Methods and Uses of Melatonin Ligands | DOMINGUEZ LOPEZ SERGIO (US) | 2016-08-04 | — | — | US | disclosed |
| EP-1973868-B1 | Novel elatonin ligands having antidepressant activity as well as sleep inducing properties | UNIV MCGILL (CA) | 2015-09-09 | — | — | EP | disclosed |
| WO-2015021535-A1 | METHODS AND USES OF MELATONIN LIGANDS | GOBBI GABRIELLA (CA) | 2015-02-19 | — | — | WO | disclosed |
| US-20150045442-A1 | NOVEL MELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES | GOBBI GABRIELLA (CA) | 2015-02-12 | — | — | US | disclosed |
| US-8791163-B2 | Melatonin ligands having antidepressant activity as well as sleep inducing properties | MCGILL UNIVERSITY (CA) | 2014-07-29 | — | — | US | disclosed |
| US-20100267836-A1 | NOVEL MELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES | UNIVERSITA DEGLI STUDI DI MILANO (IT) | 2010-10-21 | — | — | US | disclosed |
| EP-1973868-A1 | NOVEL ELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES | McGILL UNIVERSITY (CA) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007079593-A1 | NOVEL MELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES | MCGILL UNIVERSITY (CA) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221932-A1 | Methods and Uses of Melatonin Ligands | MTNR1A, MTNR1B, MC3R | CYP2D6 480/4885MTNR1A 1/4885KCNH2 483/4885 |
| US-20100267836-A1 | NOVEL MELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES | HCRTR1, HCRTR2, MTNR1A | CYP2D6 304/4885MTNR1A 3/4885KCNH2 398/4885 |
| US-20150045442-A1 | NOVEL MELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES | HCRTR1, HCRTR2, MTNR1A | CYP2D6 300/4885MTNR1A 3/4885KCNH2 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.